Trials / Completed
CompletedNCT02267343
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 493 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-4538 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-08-01
- Completion
- 2021-01-01
- First posted
- 2014-10-17
- Last updated
- 2024-05-03
Locations
49 sites across 3 countries: Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT02267343. Inclusion in this directory is not an endorsement.